Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Pfizer Drops Out Of Indiplon Development; Neurocrine To Seek New Partner

  • News

Executive Summary

Neurocrine will seek a new commercialization partner for the insomnia agent indiplon following Pfizer's decision to exit a collaboration for the drug, CEO Gary Lyons said during a June 22 conference call

You may also be interested in...



Split Indication Deals Are Lose-Lose For Partnering Firms, Boehringer Says

Companies should be wary of split indication agreements for products due to the complexities of such deals in practice, Boehringer Ingelheim Alliance Management Director Brooke Paige said Aug. 9

Split Indication Deals Are Lose-Lose For Partnering Firms, Boehringer Says

Companies should be wary of split indication agreements for products due to the complexities of such deals in practice, Boehringer Ingelheim Alliance Management Director Brooke Paige said Aug. 9

Benzodiazepines, OTCs Are As Effective As Newer Rx Sleep Agents - Article

Newer insomnia treatments are no more effective than benzodiazepines and OTC antihistamines, Consumer Reports' August 2006 "Best Buy Drugs" report says

Table

View full table

Tags:
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS047324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By